Evidence map›Paper›PMID 41690414›Full record

ArticleBiochemical pharmacology2026

Ibogalogs induce antiseizure activity in rodents by a mechanism involving 5-HT

Abdeslam Chagraoui, Paulina Kazmierska-Grebowska, Olivia Byache, Alejandro Abraham, Deborah Rudin, Bartosz Caban, Tomasz Kowalczyk, Matthias E Liechti, Daniel Wacker, Chloé Aman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abdeslam ChagraouiLaboratory Nordic: Neuroendocrine, endocrine and germinal differentiation communication - UMR 1239 (Inserm), Normandy University, UNIROUEN, Institute for Research and Innovation in Biomedicine of Normandy (IRIB), Rouen, France; Department of Medical Biochemistry, Rouen University Hospital, CHU de Rouen, France. Electronic address: abdeslam.chagraoui@univ-rouen.fr.
Paulina Kazmierska-GrebowskaDepartment of Neurobiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Olivia ByacheCentre National de la Recherche Scientifique, Institut des Neurosciences Intégratives et Cognitives d'Aquitaine, UMR 5287, Bordeaux, France.
Alejandro AbrahamDepartment of Pharmacological Sciences and Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Deborah RudinDivision of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Bartosz CabanDepartment of Neurobiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Tomasz KowalczykDepartment of Neurobiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Matthias E LiechtiDivision of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Daniel WackerDepartment of Pharmacological Sciences and Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Chloé AmanCentre National de la Recherche Scientifique, Institut des Neurosciences Intégratives et Cognitives d'Aquitaine, UMR 5287, Bordeaux, France.
Philippe De DeurwaerdèreCentre National de la Recherche Scientifique, Institut des Neurosciences Intégratives et Cognitives d'Aquitaine, UMR 5287, Bordeaux, France.
Hugo R AriasDepartment of Pharmacology and Physiology, Oklahoma State University College of Osteopathic Medicine, Tahlequah, OK, USA.

Funding

Structural Studies and Drug Discovery Illuminate Serotonin PharmacologyR35GM133504 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Daniel Wacker · 2019 to 2026
$3.4M
NIGMS NIH HHS R35 GM133504
6 · The paper itself

Abstract

The antiseizure properties of ibogalogs, including ibogaminalog (DM506), ibogainalog (IBG), and nor-IBG, were assessed in rodents using the pentylenetetrazol (PTZ)-induced seizure test. The behavioral findings indicated that ibogalogs exhibited mild acute antiseizure effects in mice, with endpoint- and time window-dependent differences between the compounds. The antiseizure effect was suppressed by volinanserin and SB242084, consistent with the involvement of 5-HT

Indexed as

AnticonvulsantsCA3 Region, HippocampalReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2CSeizuresAnimalsDose-Response Relationship, DrugMaleMiceSerotonin 5-HT2 Receptor AgonistsAnticonvulsantsReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2CSerotonin 5-HT2 Receptor Agonists5-HT(2A/2C)receptorsAntiseizure activityIbogalogsKainic acidMonoamines

Identifiers

PMID41690414
PMCPMC13140093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.